ArticleMolecular cancer therapeutics2021

Targeting CDK4/6 Represents a Therapeutic Vulnerability in Acquired BRAF/MEK Inhibitor-Resistant Melanoma.

Kelsey W Nassar et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.